LUNG CANCER

A study of air pollutant particulate matter shows that it may be a mechanistic driver for lung cancer, showing a need to curb its source.

The phase 2 NEOpredict trial of nivolumab with or without relatilmab met its primary end point of feasibility of treatment in patients with resectable non–small cell lung cancer.

In the first interview of this series, Allison Betof Warner, MD, PhD, reviews the mechanistic rationale of tumor-infiltrating lymphocytes and considers their potential use in the management of solid tumors.

Erminia Massarelli, MD, PhD, MS, discusses the efficacy outcomes of the CHRYSALIS trial of amivantamab in patients with non–small cell lung cancer and an EGFR exon 20 insertion.

In an interview with Targeted Oncology, Melina Elpi Marmarelis, MD, further discussed the findings revealed from the LACP cohort of the CHRYSALIS-2 study in non–small cell lung cancer.

During a live virtual event, Benjamin P. Levy, MD, discussed the case of a patient with non–small cell lung cancer and an EGFR exon 19 deletion. This is the second of two articles based on this event.

Top-line data from the SELECT trial of vopratelimab plus pimivalimab vs pimivalimab alone missed its primary end point of mean tumor change but showed encouraging trends for secondary end points.

Karen L. Reckamp, MD, discusses the key findings of the phase 2 Lung-MAP substudy S1800A for patients with stage IV, previously-treated non–small cell lung cancer.

The novel targeted therapy abivertinib showed efficacy in a clinical trial of patients with EGFR T790M mutations who previously received an EGFR inhibitor.

CE label expansion has been given to the VENTANA PD-L1 assay for patients with non-small cell lung cancer as a companion diagnostic for atezolizumab.

Brandon Sheffield, MD, explains the biomarkers that are important to identify before treating a patient who has been diagnosed with non–small cell lung cancer.

New findings suggest that all patients with lung cancer undergo germline testing.

The phase CANOPY-A study has missed its primary end point of disease-free survival improvement in patients with stages II to IIIA and IIIB completely resected non-small cell lung cancer.

Accelerated approval has been granted to trastuzumab deruxtecan for patients with HER2-positive unresectable or metastatic non-small cell lung cancer based on positive results from DESTINY-Lung02.

Survival outcomes of avelumab in patients with PD-L1-positive non-small cell lung cancer showed numeric improvement compared with chemotherapy, but missed the significance threshold in the JAVELIN Lung 100 study.

An easy way to double survival for patients with lung cancer is by removing the barriers to screening.

Datopotamab deruxtecan and pembrolizumab with or without platinum-based chemotherapy showed promising efficacy and a manageable safety profile in advanced/metastatic non–small cell lung cancer without actionable genomic alterations.

Pembrolizumab and etoposide continues to demonstrate improvements in survival outcomes compared with placebo and etoposide in patients with previously untreated extensive stage-small cell lung cancer.

During a live virtual event, Benjamin P. Levy, MD, discussed the results of the IMpower 133 and CASPIAN trials of immunotherapy for patients with extensive-stage small cell lung cancer.

Patients with non–small cell lung cancer who progress after first-line chemoimmunotherapy are in need of new treatment options and strategies, according to a retrospective analysis presented at the 2022 World Conference on Lung Cancer.

Treatment with nivolumab and chemotherapy in patients with stage IIIA/B non–small cell lung cancer yielded significantly improved survival and responses, according to data from the phase 2 NADIM II study.

Atezolizumab may lead to improved overall survival when compared with the best supportive care in patients with resected non–small cell lung cancer.

Pembrolizumab plus lenvatinib demonstrated promising clinical activity with no unexpected toxicities in patients with malignant pleural mesothelioma, according to results from the PEMMELA study.

Comparable outcomes seen with sintilimab vs pembrolizumab in patients with treatment-naïve metastatic non–small cell lung cancer.

Unique signaling pathways and significant differentially-expressed genes was found from 4 subgroups of patients with MET exon 14 skipping non–small cell lung cancer.